We originally initiated coverage of today’s featured stock in 2012. It has risen by more than 500% since then and we expect similar returns going forward. This innovative company is set to introduce what may be the most disruptive technology in the chemical and energy industries in years, with target markets representing tens of billions of dollars.

With key milestones ahead, deep IP, and innovative offerings that could serve as better alternatives to existing products and processes, this stock has the wind at its back. Moreover, its joint ventures with Fortune 100 companies validate and confirm the huge inherent potential in these shares.

Today we are initiating coverage of a stock that trades at an incredibly low valuation for a revenue generating company with potentially high margins and with multiple shots on goal. Plus, this relative unknown is the only pure play of its kind.

As management continues to successfully execute its business model, the overall value of the company should rise dramatically, resulting in substantial stock accumulation.

On the heels of our NFL theme yesterday, we are featuring a stock this morning that will likely resonate with many readers.

I am sure that fans all across the country were drinking beer and having a great time while watching the full slate of games, yesterday. Unfortunately, some of these fans have a serious problem with alcoholism and addiction to harmful substances.

The good news is that we are once again featuring a company that has designed what may be the holy grail of alcohol treatment. The Company’s program is so popular that it has already seen a 300% increase in enrollees in the past year, with even higher growth figures in the offing, as more clinics open around the country.

One of our favorite Opportunity Research (sponsored) companies released results last week and sales grew by 252% from last year to $14.1M with operating income increasing by 345%. The growth is outrageous which is why we believe it is an easy three-bagger.

We are issuing a trade alert on a NASDAQ company we have followed since 2011 that not only is primed to move much higher on the heels of M&A, but could be aided by the near term commencement of a short squeeze.

Fundamentally, company revenue could reach the $14M - $16M range this year, up from a few hundred thousand in 2013 and could achieve $25M+ in revenue next year, aided by recently closed and pending M&A. The stock, which has been the target of naked short selling, is primed to be driven to new levels by short covering in response to pending events, taking the fast-growing company to new highs.

Today we are initiating coverage of a company that might be the perfect answer to a market correction, given its industry and asset class. At its peak, the stock carried a market cap of $200M. Today the dual-listed stock is a fraction of that level yet the model is better than ever. That is why we are projecting a triple from current levels.

I am usually not a fan of sub-penny stocks given the inherent risk they pose. In the case of today’s profiled stock, I was compelled to make an exception. After all, the Company was profitable and posted $3.6 million in sales last year (up from $2.3M in 2010) and has a much higher gross margin than any of its competitors, including the publicly traded industry leader. It doesn’t hurt that its extremely low valuation of .3x its 2013 sales means it has room to move higher and could get a boost from the execution of its own M&A down the road.

We don’t issue more than 2 or 3 trading alerts in any given year and this is our first of 2014, so rest assured that we are highly confident that a quick 40% return is in the cards. Check out the thumbnail sketch of this unusual opportunity.

BioCorRx may have developed the holy grail of alcohol treatment, known as the Start Fresh Program, which is used by clinics across the country.The Company’s business model should result in major operating profits beginning next year as meaningful market penetration occurs.